Request for Nominations on Public Advisory Panels of the Medical Devices Advisory Committee, 45298-45299 [2017-20778]
Download as PDF
45298
Federal Register / Vol. 82, No. 187 / Thursday, September 28, 2017 / Notices
5630 Fishers Lane, Rm. 1061, Rockville,
MD 20852, and is available for viewing
by interested persons between 9 a.m.
and 4 p.m., Monday through Friday.
1. Ridley, D.B., H.G. Grabowski, and J.L. Moe,
‘‘Developing Drugs for Developing
Countries,’’ Health Affairs, vol. 25, no. 2,
pp. 313–324, 2006.
Dated: September 22, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–20799 Filed 9–27–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–0001]
Request for Nominations on Public
Advisory Panels of the Medical
Devices Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting that
any industry organizations interested in
participating in the selection of
nonvoting industry representatives to
serve on certain panels of the Medical
Devices Advisory Committee (MDAC or
Committee) in the Center for Devices
and Radiological Health (CDRH) notify
FDA in writing. FDA is also requesting
nominations for nonvoting industry
representatives to serve on certain
device panels of the MDAC in the
CDRH. A nominee may either be selfnominated or nominated by an
organization to serve as a nonvoting
industry representative. Nominations
will be accepted for current and
SUMMARY:
upcoming vacancies effective with this
notice.
DATES: Any industry organization
interested in participating in the
selection of an appropriate nonvoting
member to represent industry interests
must send a letter stating that interest to
the FDA by October 30, 2017 (see
sections I and II of this document for
further details). Concurrently,
nomination materials for prospective
candidates should be sent to FDA by
October 30, 2017.
ADDRESSES: All statements of interest
from industry organizations interested
in participating in the selection process
of nonvoting industry representative
nomination should be sent to Margaret
Ames (see FOR FURTHER INFORMATION
CONTACT). All nominations for
nonvoting industry representatives
should be submitted electronically by
accessing the FDA Advisory Committee
Membership Nomination Portal: https://
www.accessdata.fda.gov/scripts/FACT
RSPortal/FACTRS/index.cfm or by mail
to Advisory Committee Oversight and
Management Staff, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 32, Rm. 5103, Silver Spring,
MD 20993–0002. Information about
becoming a member of an FDA advisory
committee can also be obtained by
visiting FDA’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm.
FOR FURTHER INFORMATION CONTACT:
Margaret Ames, Division of Workforce
Management, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5264, Silver Spring,
MD 20993, 301–796–5960, Fax: 301–
847–8505, email: margaret.ames@
fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency is requesting nominations for
nonvoting industry representatives to
Panels
Clinical Chemistry and Clinical
Toxicology Devices Panel.
Gastroenterology and Urology Devices Panel.
General Hospital and Personal Use
Devices Panel.
Obstetrics and Gynecology Devices
Panel.
18:44 Sep 27, 2017
I. Medical Devices Advisory Committee
The Committee reviews and evaluates
data on the safety and effectiveness of
marketed and investigational devices
and makes recommendations for their
regulation. The panels engage in a
number of activities to fulfill the
functions the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) envisions
for device advisory panels. With the
exception of the Medical Devices
Dispute Resolution Panel, each panel,
according to its specialty area, advises
the Commissioner of Food and Drugs
(the Commissioner) regarding
recommended classification or
reclassification of devices into one of
three regulatory categories; advises on
any possible risks to health associated
with the use of devices; advises on
formulation of product development
protocols; reviews premarket approval
applications for medical devices;
reviews guidelines and guidance
documents; recommends exemption of
certain devices from the application of
portions of the FD&C Act; advises on the
necessity to ban a device; and responds
to requests from the agency to review
and make recommendations on specific
issues or problems concerning the safety
and effectiveness of devices. With the
exception of the Medical Devices
Dispute Resolution Panel, each panel,
according to its specialty area, may also
make appropriate recommendations to
the Commissioner on issues relating to
the design of clinical studies regarding
the safety and effectiveness of marketed
and investigational devices. The
Committee also provides
recommendations to the Commissioner
or designee on complexity
categorization of in vitro diagnostics
under the Clinical Laboratory
Improvement Amendments of 1988.
Function
Circulatory System Devices Panel
VerDate Sep<11>2014
the panels listed in the table in this
document.
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational devices for use in the circulatory and vascular systems and makes appropriate recommendations to the
Commissioner of Food and Drugs.
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational in
vitro devices for use in clinical laboratory medicine including clinical toxicology, clinical chemistry, endocrinology, and oncology and makes appropriate recommendations to the Commissioner of Food and
Drugs.
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational gastroenterology, urology, and nephrology devices and makes appropriate recommendations to the Commissioner of Food and Drugs.
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational general hospital, infection control, and personal use devices and makes appropriate recommendations to the
Commissioner of Food and Drugs.
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational devices for use in obstetrics and gynecology and makes appropriate recommendations to the Commissioner of Food and Drugs.
Jkt 241001
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
E:\FR\FM\28SEN1.SGM
28SEN1
Federal Register / Vol. 82, No. 187 / Thursday, September 28, 2017 / Notices
45299
Panels
Function
Ophthalmic Devices Panel ..............
Reviews and evaluates data concerning the safety and effectiveness of marketed and investigational devices for use in the eye and makes appropriate recommendations to the Commissioner of Food and
Drugs.
II. Qualifications
Persons nominated for the device
panels should be full-time employees of
firms that manufacture products that
would come before the panel, or
consulting firms that represent
manufacturers, or have similar
appropriate ties to industry.
III. Selection Procedure
Any industry organization interested
in participating in the selection of an
appropriate nonvoting member to
represent industry interests should send
a letter stating that interest to the FDA
contact (see FOR FURTHER INFORMATION
CONTACT) within 30 days of publication
of this document (see DATES). Within the
subsequent 30 days, FDA will send a
letter to each organization that has
expressed an interest, attaching a
complete list of all such organizations;
and a list of all nominees along with
their current resumes. The letter will
also state that it is the responsibility of
the interested organizations to confer
with one another and to select a
candidate, within 60 days after the
receipt of the FDA letter, to serve as the
nonvoting member to represent industry
interests for a particular device panel.
The interested organizations are not
bound by the list of nominees in
selecting a candidate. However, if no
individual is selected within 60 days,
the Commissioner will select the
nonvoting member to represent industry
interests.
IV. Application Procedure
Individuals may self-nominate and/or
an organization may nominate one or
more individuals to serve as a nonvoting
industry representative. Contact
information, a current curriculum vitae,
and the name of the panel of interest
should be sent to the FDA Advisory
Committee Membership Nomination
Portal (see ADDRESSES) within 30 days of
publication of this document (see
DATES). FDA will forward all
nominations to the organizations
expressing interest in participating in
the selection process for the particular
device panels listed in the table.
(Persons who nominate themselves as
nonvoting industry representatives will
not participate in the selection process).
FDA seeks to include the views of
women and men, members of all racial
and ethnic groups, and individuals with
VerDate Sep<11>2014
18:44 Sep 27, 2017
Jkt 241001
and without disabilities on its advisory
committees and, therefore encourages
nominations of appropriately qualified
candidates from these groups.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to advisory committees.
Dated: September 22, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–20778 Filed 9–27–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[Document Identifier: OS–0990–0330]
Agency Information Collection
Request. 60-Day Public Comment
Request
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
In compliance with the
requirement of the Paperwork
Reduction Act of 1995, the Office of the
Secretary (OS), Department of Health
and Human Services, is publishing the
following summary of a proposed
collection for public comment.
DATES: Comments on the ICR must be
received on or before November 27,
2017.
SUMMARY:
Submit your comments to
Sherrette.Funn@hhs.gov or by calling
(202)795–7714.
FOR FURTHER INFORMATION CONTACT:
When submitting comments or
requesting information, please include
the document identifier 0990–0330–60D
and project title for reference, to
Sherrette.funn@hhs.gov, the Reports
Clearance Officer Sherrette Funn, call
202–795–7714.
SUPPLEMENTARY INFORMATION: Interested
persons are invited to send comments
regarding this burden estimate or any
other aspect of this collection of
information, including any of the
following subjects: (1) The necessity and
utility of the proposed information
collection for the proper performance of
the agency’s functions; (2) the accuracy
of the estimated burden; (3) ways to
enhance the quality, utility, and clarity
of the information to be collected; and
ADDRESSES:
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
(4) the use of automated collection
techniques or other forms of information
technology to minimize the information
collection burden.
Title: Appellant Climate Survey,
Revision.
Abstract: The Office of Medicare
Hearings and Appeals (OMHA) requests
revision to a previously approved
information collection request from the
Office of Management and Budget
(OMB). The annual OMHA Appellant
Climate Survey is a survey of Medicare
beneficiaries, providers, suppliers, or
their representatives who participated
in a hearing before an Administrative
Law Judge (ALJ) from OMHA.
Appellants dissatisfied with the
outcome of their Level 2 Medicare
appeal may request a hearing before an
OMHA ALJ. The Appellant Climate
Survey will be used to measure
appellant satisfaction with their OMHA
appeals experience, as opposed to their
satisfaction with a specific ruling.
OMHA was established by the Medicare
Prescription Drug, Improvement, and
Modernization Act (MMA) of 2003 (Pub.
L. 108–173) and became operational on
July 1, 2005. The MMA legislation and
implementing regulations issued on
March 8, 2007 instituted a number of
changes in the appeals process. The
MMA legislation also directed HHS to
consider the feasibility of conducting
hearings using telephone or videoteleconference (VTC) technologies. In
carrying out this mandate, OMHA
makes use of both teleconferencing and
VTC to provide appellants with a vast
nationwide network of access points for
hearings close to their homes. The first
3-year administration cycle of the
OMHA survey began in fiscal year (FY)
2008, a second 3-year cycle began in
FY2011, and third 3-year cycle began in
FY2014. The survey will continue to be
conducted annually over a 3-year period
with the next data collection cycle
beginning in FY2018. Data collection
instruments and recruitment materials
will be offered in English and Spanish.
Total burden for survey respondents is
100.00 hours each year.
Affected Public: Survey respondents
will consist of Medicare beneficiaries
and non-beneficiaries (i.e., providers,
suppliers), who participated in a
hearing before an OMHA ALJ. OMHA
will draw a representative, nonredundant sample of appellants whose
E:\FR\FM\28SEN1.SGM
28SEN1
Agencies
[Federal Register Volume 82, Number 187 (Thursday, September 28, 2017)]
[Notices]
[Pages 45298-45299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20778]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2017-N-0001]
Request for Nominations on Public Advisory Panels of the Medical
Devices Advisory Committee
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is requesting that any
industry organizations interested in participating in the selection of
nonvoting industry representatives to serve on certain panels of the
Medical Devices Advisory Committee (MDAC or Committee) in the Center
for Devices and Radiological Health (CDRH) notify FDA in writing. FDA
is also requesting nominations for nonvoting industry representatives
to serve on certain device panels of the MDAC in the CDRH. A nominee
may either be self-nominated or nominated by an organization to serve
as a nonvoting industry representative. Nominations will be accepted
for current and upcoming vacancies effective with this notice.
DATES: Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests must send a letter stating that interest to the FDA by
October 30, 2017 (see sections I and II of this document for further
details). Concurrently, nomination materials for prospective candidates
should be sent to FDA by October 30, 2017.
ADDRESSES: All statements of interest from industry organizations
interested in participating in the selection process of nonvoting
industry representative nomination should be sent to Margaret Ames (see
FOR FURTHER INFORMATION CONTACT). All nominations for nonvoting
industry representatives should be submitted electronically by
accessing the FDA Advisory Committee Membership Nomination Portal:
https://www.accessdata.fda.gov/scripts/FACTRSPortal/FACTRS/index.cfm or
by mail to Advisory Committee Oversight and Management Staff, Food and
Drug Administration, 10903 New Hampshire Ave., Bldg. 32, Rm. 5103,
Silver Spring, MD 20993-0002. Information about becoming a member of an
FDA advisory committee can also be obtained by visiting FDA's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm.
FOR FURTHER INFORMATION CONTACT: Margaret Ames, Division of Workforce
Management, Center for Devices and Radiological Health, Food and Drug
Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 5264, Silver
Spring, MD 20993, 301-796-5960, Fax: 301-847-8505, email:
margaret.ames@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The Agency is requesting nominations for
nonvoting industry representatives to the panels listed in the table in
this document.
I. Medical Devices Advisory Committee
The Committee reviews and evaluates data on the safety and
effectiveness of marketed and investigational devices and makes
recommendations for their regulation. The panels engage in a number of
activities to fulfill the functions the Federal Food, Drug, and
Cosmetic Act (the FD&C Act) envisions for device advisory panels. With
the exception of the Medical Devices Dispute Resolution Panel, each
panel, according to its specialty area, advises the Commissioner of
Food and Drugs (the Commissioner) regarding recommended classification
or reclassification of devices into one of three regulatory categories;
advises on any possible risks to health associated with the use of
devices; advises on formulation of product development protocols;
reviews premarket approval applications for medical devices; reviews
guidelines and guidance documents; recommends exemption of certain
devices from the application of portions of the FD&C Act; advises on
the necessity to ban a device; and responds to requests from the agency
to review and make recommendations on specific issues or problems
concerning the safety and effectiveness of devices. With the exception
of the Medical Devices Dispute Resolution Panel, each panel, according
to its specialty area, may also make appropriate recommendations to the
Commissioner on issues relating to the design of clinical studies
regarding the safety and effectiveness of marketed and investigational
devices. The Committee also provides recommendations to the
Commissioner or designee on complexity categorization of in vitro
diagnostics under the Clinical Laboratory Improvement Amendments of
1988.
------------------------------------------------------------------------
Panels Function
------------------------------------------------------------------------
Circulatory System Devices Panel.. Reviews and evaluates data
concerning the safety and
effectiveness of marketed and
investigational devices for use in
the circulatory and vascular
systems and makes appropriate
recommendations to the Commissioner
of Food and Drugs.
Clinical Chemistry and Clinical Reviews and evaluates data
Toxicology Devices Panel. concerning the safety and
effectiveness of marketed and
investigational in vitro devices
for use in clinical laboratory
medicine including clinical
toxicology, clinical chemistry,
endocrinology, and oncology and
makes appropriate recommendations
to the Commissioner of Food and
Drugs.
Gastroenterology and Urology Reviews and evaluates data
Devices Panel. concerning the safety and
effectiveness of marketed and
investigational gastroenterology,
urology, and nephrology devices and
makes appropriate recommendations
to the Commissioner of Food and
Drugs.
General Hospital and Personal Use Reviews and evaluates data
Devices Panel. concerning the safety and
effectiveness of marketed and
investigational general hospital,
infection control, and personal use
devices and makes appropriate
recommendations to the Commissioner
of Food and Drugs.
Obstetrics and Gynecology Devices Reviews and evaluates data
Panel. concerning the safety and
effectiveness of marketed and
investigational devices for use in
obstetrics and gynecology and makes
appropriate recommendations to the
Commissioner of Food and Drugs.
[[Page 45299]]
Ophthalmic Devices Panel.......... Reviews and evaluates data
concerning the safety and
effectiveness of marketed and
investigational devices for use in
the eye and makes appropriate
recommendations to the Commissioner
of Food and Drugs.
------------------------------------------------------------------------
II. Qualifications
Persons nominated for the device panels should be full-time
employees of firms that manufacture products that would come before the
panel, or consulting firms that represent manufacturers, or have
similar appropriate ties to industry.
III. Selection Procedure
Any industry organization interested in participating in the
selection of an appropriate nonvoting member to represent industry
interests should send a letter stating that interest to the FDA contact
(see FOR FURTHER INFORMATION CONTACT) within 30 days of publication of
this document (see DATES). Within the subsequent 30 days, FDA will send
a letter to each organization that has expressed an interest, attaching
a complete list of all such organizations; and a list of all nominees
along with their current resumes. The letter will also state that it is
the responsibility of the interested organizations to confer with one
another and to select a candidate, within 60 days after the receipt of
the FDA letter, to serve as the nonvoting member to represent industry
interests for a particular device panel. The interested organizations
are not bound by the list of nominees in selecting a candidate.
However, if no individual is selected within 60 days, the Commissioner
will select the nonvoting member to represent industry interests.
IV. Application Procedure
Individuals may self-nominate and/or an organization may nominate
one or more individuals to serve as a nonvoting industry
representative. Contact information, a current curriculum vitae, and
the name of the panel of interest should be sent to the FDA Advisory
Committee Membership Nomination Portal (see ADDRESSES) within 30 days
of publication of this document (see DATES). FDA will forward all
nominations to the organizations expressing interest in participating
in the selection process for the particular device panels listed in the
table. (Persons who nominate themselves as nonvoting industry
representatives will not participate in the selection process).
FDA seeks to include the views of women and men, members of all
racial and ethnic groups, and individuals with and without disabilities
on its advisory committees and, therefore encourages nominations of
appropriately qualified candidates from these groups.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.
Dated: September 22, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-20778 Filed 9-27-17; 8:45 am]
BILLING CODE 4164-01-P